Liquidia (FRA:LT4) Other Long-Term Liabilities : €-0.00 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Liquidia Other Long-Term Liabilities?

Liquidia's other long-term liabilities for the quarter that ended in Mar. 2025 was €-0.00 Mil.

Liquidia's quarterly other long-term liabilities declined from Sep. 2024 (€0.00 Mil) to Dec. 2024 (€-0.00 Mil) but then increased from Dec. 2024 (€-0.00 Mil) to Mar. 2025 (€-0.00 Mil).

Liquidia's annual other long-term liabilities increased from Dec. 2022 (€-0.00 Mil) to Dec. 2023 (€0.00 Mil) but then declined from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€-0.00 Mil).

Liquidia Other Long-Term Liabilities Historical Data

The historical data trend for Liquidia's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Liquidia Other Long-Term Liabilities Chart

Liquidia Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Long-Term Liabilities

Get a 7-Day Free Trial

Liquidia Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Liquidia Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Liquidia Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Liquidia's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Liquidia Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Liquidia Corp (FRA:LT4) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

LQDA:USA

Address

419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560

Website

https://www.liquidia.com

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Liquidia Headlines

No Headlines